Sugi Predict

Sugi Predict / Compounds / SCHEMBL7894772

SCHEMBL7894772

SCHEMBL7894772

CC(=O)Nc1nc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2o1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 18/20 0.71
▸ PIK3CD O00329 18/20 0.61
▸ PIK3CA P42336 18/20 0.61
▸ PIK3CB P42338 18/20 0.61
▸ PIK3CG P48736 17/20 0.61
▸ RICTOR Q6R327 1/20 0.61
▸ RPTOR Q8N122 1/20 0.61
▸ PIK3C3 Q8NEB9 1/20 0.61
▸ MAPKAP1 Q9BPZ7 1/20 0.61
▸ MLST8 Q9BVC4 1/20 0.61
▸ BMPR1B O00238 1/20 0.60
▸ RIPK2 O43353 1/20 0.60
▸ STK16 O75716 1/20 0.60
▸ STK10 O94804 1/20 0.60
▸ MAP4K4 O95819 1/20 0.60
▸ RET P07949 1/20 0.60
▸ PDGFRB P09619 1/20 0.60
▸ FGFR1 P11362 1/20 0.60
▸ PRKCA P17252 1/20 0.60
▸ DCK P27707 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7903524 0.94 MTOR (0.71) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL7901532 0.83 MTOR (1.00) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL16127375 0.83 BMPR1B (0.86) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL19299482 0.81 MTOR (0.77) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL7902843 0.80 MTOR (0.57) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL1787523 0.80 PIK3CD (0.62) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL16127231 0.80 MTOR (0.75) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18799891 0.78 PIK3CD (0.57) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18613724 0.78 MTOR (0.69) MTORPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18613714 0.78 MTOR (0.63) MTORPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172858-B2 Combination pharmaceutical compositions and uses thereof INTELLIKINE LLC (US) 2019-01-08 — — US disclosed
US-20180117060-A1 COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE MILLENNIUM PHARM INC (US) 2018-05-03 — — US disclosed
US-9724354-B2 Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-08-08 — — US disclosed
US-9724354-B2 Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-08-08 — — US disclosed
US-20170209448-A1 TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS INTELLIKINE LLC 2017-07-27 — — US disclosed
US-20170209448-A1 TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS INTELLIKINE LLC 2017-07-27 — — US disclosed
US-9669032-B2 Enhanced treatment regimens using mTOR inhibitors INTELLIKINE LLC (US) 2017-06-06 — — US disclosed
US-9669032-B2 Enhanced treatment regimens using mTOR inhibitors INTELLIKINE LLC (US) 2017-06-06 — — US disclosed
US-20160287596-A1 Benzoxazole Kinase Inhibitors and Methods of Use FAETH THERAPEUTICS, INC. 2016-10-06 — — US disclosed
US-20160287596-A1 Benzoxazole Kinase Inhibitors and Methods of Use FAETH THERAPEUTICS, INC. 2016-10-06 — — US disclosed
US-8476282-B2 Benzoxazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2013-07-02 — — US disclosed
US-8476431-B2 Benzoxazole kinase inhibitors and methods of use Itellikine LLC (US) 2013-07-02 — — US disclosed
US-8450480-B2 — — 2013-05-28 — — US disclosed
US-8450329-B2 — — 2013-05-28 — — US disclosed
US-8450329-B2 — — 2013-05-28 — — US disclosed
US-8450480-B2 — — 2013-05-28 — — US disclosed
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF INTELLIKINE LLC (US) 2012-11-22 — — US disclosed
US-20100190749-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-29 — — US disclosed
US-20100190749-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-29 — — US disclosed
US-20100184760-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160287596-A1 Benzoxazole Kinase Inhibitors and Methods of Use BMX, MTOR, PDPK1 MTOR 2/4885PIK3CD 13/4885PIK3CA 4/4885
US-20100184760-A1 Benzoxazole kinase inhibitors and methods of use BMX, MTOR, PDPK1 MTOR 2/4885PIK3CD 13/4885PIK3CA 4/4885
US-20180117060-A1 COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE AURKC, MTOR, AURKA MTOR 2/4885PIK3CD 150/4885PIK3CA 132/4885
US-20100190749-A1 Benzoxazole kinase inhibitors and methods of use BMX, MTOR, PDPK1 MTOR 2/4885PIK3CD 13/4885PIK3CA 4/4885
US-10172858-B2 Combination pharmaceutical compositions and uses thereof CDC25C, CCNC, CDC25B MTOR 424/4885PIK3CD 446/4885PIK3CA 363/4885
US-20170209448-A1 TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS MPL, MTX2, SLC10A1 MTOR 3565/4885PIK3CD 2330/4885PIK3CA 1540/4885
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF MTOR, AKT2, MTMR1 MTOR 1/4885PIK3CD 24/4885PIK3CA 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.